







UCI 19-49

Cabo + Ipi/Nivo + TACE

Coord: H. Nguyen **Accrual: 19/35**

UCI 23-75/ROUTE 90

Eye90 microspheres

Coord: M. Duron Accrual: 2/15

UCI 22-211

MED1572 (IgG1 mAb) ± Bev Slot request required Coord: C. Kang Accrual: 3/8

UCI 23-104

Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab Suspended until Q4 2025 Coord: S. Duong Accrual: 3/7

UCI 23-86

Atezolizumab ± Bevacizumab (Child-Pugh B7 and B8)

> Coord: M. Duron Accrual: 0/10

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab (Slot request required)

> Coord: H. Nguyen Accrual: 8/10

UCI 16-94

TATE + Nivolumab (includes gastric/GEJ)

Coord: S. Duong Accrual: 29/40

UCI 23-215

AZD5851 (GPC3 Autologous CAR-T) **Central testing for GPC3**

> Coord: J. Balangue Accrual: 0/5





SYSTEMIC + OPERATIVE

ETCTN 10608

Gemcitabine + Cisplatin + Durva Neo/Adjuvant for highrisk resectable ICC

> Coord: H. Nguyen Accrual: 2/3

UCI 23-99

Randomize, adjuvant Rilvegostomig/placebo + capecitabine or gem/cisplatin after BTC resection

> Coord: H. Nguyen Accrual: 0/8

FIRST LINE

UCI 22-212

(includes Ampullary)

Durvalumab + any gemcitabine-based regimen LIMITED SLOTS

> Coord: H. Nguyen Accrual: 5/8

UCI 22-211

MED1572 (IgG1 mAb) or AZD2936 (TIGIT) ± gemcitabine and cisplatin

TBD more slots to be released

> Coord: C. Kang Accrual: 1/8

SECOND LINE+

Open to Accrual

ETCTN-10276

M3814 ± Avelumab + **Hypofraction Radiation**

> Coord: C. Kang Accrual: 3/5

UCI 23-200

AZD0901 (CLND18 ADC) Central prescreening

> Coord: C. Kang Accrual: 4/10



Low Accruing Pending Activation/Suspended



PERIOPERATIVE

A021806

Neo/adjuvant vs adjuvant **mFOLFIRINOX**

> Coord: J. Balangue Accrual: 0/15

BORDERLINE/ **LOCALLY ADVANCED**

ETCTN-10366

M3814 (Peposertib) + radiation therapy Coord: S. Duong Accrual: 6/8

ETCTN-10464

Olaparib with Durvalumab + radiation therapy

> Coord: S. Duong Accrual: 1/5

UCI 23-134

Padeliporfin Vascular targeted photodynamic therapy

Pancreatic head/uncinate w/SMA

Coord: C. Kang Accrual: 0/8

FIRST LINE LA/METASTATIC

Open to Accrual

S2001

Olaparib +/- Pembrolizumab (BRCA 1/2, STABLE DISEASE)

> Coord: J. Balangue Accrual: 2/4

UCI 23-200

AZD0901 (CLND18 ADC) with NAL-IRI or Gemcitabine Investigator discretion

> Coord: S. Duong Accrual: 4/10

UCI 22-51

ASP2138 (CLDN18.2 BiTe) with **FOLFIRINOX**

> Coord: P. Yang Accrual: 18/20

UCI 24-82

IK-595 (MEK/RAF Inhibitor) with Gemcitabine/nab-paclitaxel

KRAS mutations

Coord: C. Kang Accrual: 1/10

SECOND LINE

Low Accruing Pending Activation/Suspended

ETCTN 10522

CA4948 + gemcitabine + nabpaclitaxel

> Coord: H. Nguyen Accrual: 3/4

A022106

Nab-paclitaxel + Gemcitabine ± Cisplatin BRCA1/2 or PALB2 **PD** on 1L FOLFIRINOX

> Coord: J. Balangue Accrual: 0/3

RECURRENT METASTATIC

UCI 24-08

SPEDOX -6 (Protein encapsulated doxorubicin)

> Coord: TBD Pending SIV

Review Biomarker Based Solid Tumors Pages 6 and 7





ADJUVANT

S2104

Capecitabine + Temozolomide vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue Accrual: 0/2

SECOND LINE

ETCTN 10479 Lu-177 + Sunitinib

Well or moderately differentiated PNET Up to one line of systemic

therapy not including somatostatin

Coord: H. Nguyen Accrual: 0/3

SECOND LINE+

ETCTN 10558

Lu-177 ± Triapine

NET w/positive 68 or 64 **DOTATATE** on scans

> Coord: H. Nguyen Accrual: 0/3



sed

O

0

iomarker

 $\mathbf{\Omega}$



Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual

Low Accruing Pending Activation/Suspended

HER2

TISSUE FACTOR

KRAS/NRAS

GERMLINE MUTATIONS

UCI 20-67

DF1001 +/- nivolumab

Coord: M. Nguyen **Accrual: 18/20**

UCI 21-146 MRG004A (TF ADC)

Coord: M. Duron Accrual: 5/11

UCI 21-53

LY3537982 (KRAS G12C Inhibitor)

> Coord: J. Choe Accrual: 7/8

ETCTN-10528 Novobiocin (POLθ) Germline mutations

Coord: H. Nguyen Accrual: 0/5

CLAUDIN 18.2

UCI 22-51

ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

Coord: P. Yang **Accrual: 18/20**

EpCAM

UCI 23-85

BA3182 (CAB T-cell: EpCAM)

All solid tumors (central **EPCAM** testing)

> Coord: H. Nguyen Accrual: 0/3

UCI 22-87

RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang Accrual: 21/25

UCI 24-82

NRAS, KRAS, BRAF mutations

Local testing; contact CRC for specific tumor types

> Coord: C. Kang Accrual: 1/10

GERM/SOMATIC MUTATIONS

UCI 23-162

IMP1734 (PARP1)

PDAC Cohort 1A: BRCA1/2, PALB2, RAD51B/C/D

Coord: J. Balangue

EGFR

UCI 22-171

EGFR TriNKET +/- Nivolumab (Central testing)

> Coord: M. Nguyen Accrual: 4/15



Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

Open to Accrual Low Accruing Pending Activation/Suspended

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: M. Duron Accrual: 10/12

UCI 21-124

ctDNA collection during HBP workup

> Coord: J. Balangue Accrual: 14/17

UCI 23-10/PRECEDE

(Blood collection for early detection of pancreatic cancer)

Pending budget/contract

